News
SOTIO Reports Promising Preclinical Data on Antibody-Drug Conjugates SOT109 and SOT106, Underscoring Best-in-Class Potential for Solid Tumor Treatments
• SOT109 (targeting cadherin-17) exhibits potent efficacy and a favorable safety profile in preclinical models of colorectal cancer; currently in IND-enabling stage with IND filing anticipated in 2026;
• SOT106 (targeting LRRC15) exhibits robust preclinical efficacy in mesenchymal tumors, including broad subset of sarcomas.
SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, this week presented preclinical data on two of its leading antibody-drug conjugate (ADC) candidates, SOT109 and SOT106, at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, IL.
SOTIO to Present Preclinical Data on Lead Antibody-Drug Conjugates, SOT106 and SOT109, at 2025 AACR Annual Meeting
SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced it will present new data from two of its antibody-drug conjugate (ADC) programs for the treatment of solid tumors, showcasing advancements in its innovative pipeline. The presentations will take place at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, IL from April 25-30, 2025.
SOTIO Exercises Option for Novel Antibody-Drug Conjugate Program under Agreement with LegoChem Biosciences
- SOT106 is an antibody-drug conjugate (ADC) targeting an attractive surface antigen expressed on multiple solid tumors.
- Preclinical efficacy and tolerability studies of SOT106 show promising results across multiple solid tumor indications and a beneficial therapeutic index.
- SOTIO is actively exploring additional tumor targets to expand the collaboration with LegoChem Biosciences to up to five ADC programs.
SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, today announced that it has exercised its first of five exclusive, target-specific options with LegoChem Biosciences (LCB, KOSDAQ: 141080) for antibody-drug conjugate (ADC) SOT106, which is currently being evaluated in preclinical studies across a multitude of solid tumor indications.
SOTIO Biotech B.V.
Zuidplein 168
1077 XV Amsterdam
Netherlands
Zuidplein 168
1077 XV Amsterdam
Netherlands
SOTIO Biotech a.s.
Českomoravská 2532/19b
190 00 Prague 9
Czech Republic
Českomoravská 2532/19b
190 00 Prague 9
Czech Republic
SOTIO Biotech AG
Lichtstrasse 35 - WSJ-210
4056 Basel
Switzerland
Lichtstrasse 35 - WSJ-210
4056 Basel
Switzerland
SOTIO Biotech Inc.
180 Canal St., Suite 300
Boston, MA 02114
USA
180 Canal St., Suite 300
Boston, MA 02114
USA
